Galena Biopharma, Inc. (GALE)
Shares of this biopharmaceutical company, which specializes in developing and commercializing oncology drugs, have tumbled nearly 55% over the past year, following allegations that the company was paying a marketing firm called The DreamTeam Group to pump its stock. Company insiders made millions of dollars by selling company shares during that period, and the biotech company is still under active SEC investigation.
However, since then, the company has moved mountains in order to distance itself from its scandalous past. In a drastic change, nearly half of Galena’s management has been replaced with industry veterans. Also, the company still has an impressive product pipeline and is seeing significant advancements in its promising new drug NeuVax, which is used to prevent recurring cancers in survivors. Also, its products Abstral and Zuplenz are showing robust performance.
We believe that the shares are undervalued at present, and that despite the scandal, the essential science behind the business remains intact, making it a worthwhile investment.
The stock has been seeing positive estimate revision activity over the past month, as the current year loss consensus estimate has narrowed 2.9% over the same time frame.
Zacks Rank #2 (Buy)
I am not a Republican, but I can tell you one thing. That is there is absolutely no scientific proof that the CO2 is causing Global Warming. Those who push it, do it, to line their pockets. Those who believe them are their Useful Idiots!
Your spot on. That is what all the stimulus money was supposed to be used for. All those shovel ready jobs. By blocking the pipeline he won't even allow private money to be put to productive use. Obama won't be happy until he drags America economy down to the level of Greece.
Accuray and Christie InnoMed Sign Exclusive Sales Agent Agreements for Radiation Therapy Systems in Canada... copy and paste following in your browser.
Problem is previous congresses mostly controlled by Democrats have given away to much of their power to the Executive branch so that we have become a nation of regulation instead of a nation of legislation. It is time to dial it back.
I use to own IRSG, now I own both TITXF and TRXC. I think there is room enough for all 3 devices.
Subject: How I am Spending My Retirement.
Here in Syracuse, NY it has been the coldest February since they started keeping records in 1902. Average temp has been 10.4 degrees, which is 15 degree below average. We have not broken freezing this month and the highest prediction for the rest of the week is 20 degrees on Saturday. Next coldest month was February 1934 with average temp of 12.5 degrees. Sunday paper showed a picture of Lake Ontario 40 miles North of here with 86 % frozen over. Ontario is a deep lake so it rarely freezes. The east end of Lake Erie is frozen solid. We have double the amount of snow for February, 55 inches, versus average of 25 inches. It has snowed every day this month, which is another record. Since there has been no thaw this month the snow bank are up to my shoulders. I have a plastic push shovel and a Troy Built Plastic Snow Blower with 221 CC engine, It is very light and easy to operate. It works very well because all the power is used to throw the snow. There is no power going to the wheels, but because it is light and the blade pulls it forward it is not needed. I don't believe man has much effect of Global Climate changes, but I wish we could make it warmer. Just a little bit...
Sort of like Musical Chairs with half the chairs missing!
The primary outcome was observation within 1 year after diagnosis. Observation was defined as absence of any accepted treatment for localized prostate cancer, including surgery, radiotherapy, cryoablation, and primary androgen deprivation therapy. The authors defined low-risk disease in accordance with the D'Amico classification system.
The search of the SEER database identified 66,499 men with newly diagnosed localized prostate cancer, of whom 34% met criteria for low risk, 40% intermediate risk, and 26% high risk. Subsequently 12,007 (18%) entered observation within a year of diagnosis.
Use of observation increased modestly but significantly (P
"Our initial results in select patients with renal tumors revealed the short-term safety and efficacy of SRS," the authors concluded. "Single-fraction delivery as an outpatient procedure can avoid treatment-related loss of renal function and hemodialysis. It is a feasible option in patients who are not candidates for alternative treatment modalities.
"To date oncologic results are comparable to those of other ablative techniques for renal tumors and functional results have been excellent. Further studies are needed to determine the limits of SRS in this setting and assess long-term oncologic and functional results."
Observation for Low-Risk Prostate Ca Edges Upward
The proportion of men with low-risk prostate cancer entering observation increased by more than 50% from 2004 to 2009 but remained less than 30%, analysis of a national database showed.
Overall, use of observation increased slightly from 17% to 20% during the 5-year period but jumped from 18% to 29% in the subgroup of men with low-risk disease. The odds for observation doubled for men in the 66-to-69 age group, those with low-risk disease, and patients with no comorbidities, Chad Ritch, MD, MBA, of the University of Miami, and colleagues reported online in the Journal of Urology.
The rationale for the study came from concern about overtreatment of localized prostate cancer, particularly low-risk disease. Moreover, uncertainty exists about the uptake of observation (surveillance) as a disease-management strategy. The authors had a particular interest in temporal trends in the use of observation for men with low-risk disease "who were young and healthy enough to undergo treatment."
Ritch and colleagues retrospectively analyzed of the Medicare-linked Surveillance, Epidemiology, and End Results (SEER) database. They identified all men with newly diagnosed localized prostate cancer from 2004 through 2009.
The Cyberknife was used for this. article copied from Charles Bankhead Staff Writer, MedPage Today
OncoBriefs: Radiosurgical Success in Renal Cancer
Single-fraction stereotactic radiosurgery (SRS) for unresectable renal tumors led to near-100% local disease control at 9 months in avoidance of nephrectomy, results of a small German study showed.
All but one of 45 treated tumors remained in remission or stable at 9 months following the single treatment session. Lesion shrinkage occurred in 38 of the tumors, including complete remission of 19 tumors, Michael Staehler, MD, of Ludwig Maximilians Universityin Munich, and colleagues reported online in the Journal of Urology.
Single-Fraction Radiosurgery for Renal Tumors
The 45-tumor case-control study involved 40 patients who had impaired renal function associated with an unresectable tumor or for whom nephrectomy was the only treatment option. The study population consisted of 11 patients with transitional cell cancer (TCC) and 29 with renal cell cancer (RCC).
The patients had a median age of 64, median tumor volume of 42 cm2 for TCC and 33.7 cm2 for RCC, and 29 patients had undergone contralateral nephrectomy and had a single remaining kidney.
All surgical procedures were performed with the same type of robotic radiosurgery system. Median follow-up was 28 months and ranged from 6 to 78.3 months.
Treated lesions consisted of 15 TCC tumors and 30 RCC tumors. By RECIST criteria, treatment led to remission in 39 of the 45 lesions, including 19 complete remissions, 13 lesions with more than 30% reduction in diameter, and six lesions with lesser reductions in baseline diameter. None of the TCC lesions was detectable at follow-up.
Kidney function remained stable from baseline (76.8 mL/min/1.73 m2) to last follow-up (70.3 mL/min/1.73 m2). Median progression-free survival and overall survival had yet to be reached.